The injectable diabetes medicine Victoza (liraglutide), a member of the class of medicines known as GLP-1 agonists, is effective in children and adolescents ages 10–17 with type 2 diabetes, according to a new study in The New England Journal of Medicine.
In the phase ELLIPSE study, Victoza combined with metformin significantly reduced A1C levels (a measure of glucose control over the previous 2–3 months) compared to placebo (inactive treatment) with metformin: Victoza reduced A1C by 0.64% and 0.5%, respectively, at 26 and 52 weeks, compared to placebo, which caused a rise of 0.42% and 0.8%.
According to lead researcher William Tamborlane, MD, “These data represent a potential new treatment option for lowering blood sugar in children and adolescents with type 2 diabetes.”
Victoza is currently approved for use along with diet and exercise in adults with type 2 diabetes. Manufacturer Novo Nordisk has submitted the results of the trial to the U.S. Food and Drug Administration (FDA) to support a labeling extension.
Want to learn more about type 2 diabetes in children? Read “Children and Type 2 Diabetes: What’s New?” and “Recognizing Type 2 Diabetes in Children and Adolescents.”